Randomized, controlled, proof-of-concept trial of gefapixant for endometriosis-related pain
Open Access
- 12 September 2024
- journal article
- Published by Elsevier in Fertility and Sterility
- Vol. 123 (2) , 280-288
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Endometriosis is a chronic systemic disease: clinical challenges and novel innovationsThe Lancet, 2021
- Medical therapy options for endometriosis related pain, which is better? A systematic review and network meta-analysis of randomized controlled trialsJournal of Gynecology Obstetrics and Human Reproduction, 2021
- Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trialThe Lancet Respiratory Medicine, 2020
- Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic coughPulmonary Pharmacology & Therapeutics, 2019
- Epidemiology of endometriosis and its comorbiditiesEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2017
- P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 studyThe Lancet, 2015
- Treatment of pelvic pain associated with endometriosis: a committee opinionFertility and Sterility, 2014
- Endometriosis and Mechanisms of Pelvic PainJournal of Minimally Invasive Gynecology, 2009
- Development of the Short Form Endometriosis Health Profile Questionnaire: The EHP-5Quality of Life Research, 2004
- Comparative analysis of two ratesStatistics in Medicine, 1985